Checkpoint Therapeutics (CKPT) - Long-Term Debt to Capital

Checkpoint Therapeutics (CKPT) is accelerating cancer drug discovery by implementing AI models and robotics to digitize laboratory testing. A stable moat is provided by the creation of an affordable skin therapy analogue currently awaiting regulatory approval. The stock price history reflects the dynamics of a company whose potential relies on the sale of chemotherapy-free antibodies, with the current metric standing at 0.00.

This indicator determines the degree of long-term financing dependence on the company's own funds. By analyzing the long-term financial leverage ratio, an investor assesses the stability of the capital structure. The metric is calculated as the ratio of liabilities with a maturity of over one year to equity capital. For Checkpoint Therapeutics (CKPT), a low level of borrowing is critical due to the high cash burn associated with research. Risks of FDA delays regarding cosibelimab make additional share offerings more likely than securing loans.